Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Working Capital Changes (2016 - 2025)

Neurocrine Biosciences' Other Working Capital Changes history spans 16 years, with the latest figure at $43.7 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 272.05% year-over-year to $43.7 million; the TTM value through Dec 2025 reached $44.4 million, up 44300.0%, while the annual FY2025 figure was $44.4 million, 44300.0% up from the prior year.
  • Other Working Capital Changes reached $43.7 million in Q4 2025 per NBIX's latest filing, up from $200000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $43.7 million in Q4 2025 to a low of -$25.4 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is $3.6 million, with a median of $2.4 million recorded in 2021.
  • The largest YoY upside for Other Working Capital Changes was 6366.67% in 2024 against a maximum downside of 2053.85% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.5 million in 2021, then tumbled by 333.33% to -$3.5 million in 2022, then surged by 137.14% to $1.3 million in 2023, then plummeted by 2053.85% to -$25.4 million in 2024, then surged by 272.05% to $43.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Other Working Capital Changes are $43.7 million (Q4 2025), $200000.0 (Q3 2025), and -$7.4 million (Q2 2025).